drugset / Trial / NCT05442190
Topical SGX302 for Mild-to-Moderate Psoriasis
RandomizedSequentialQuadruple-blindTreatment
Summary
To evaluate SGX302 (topical hypericin ointment and gel) with visible light in an initial 18-week treatment course for improving lesions in patients with mild-to-moderate psoriasis.
Timeline
- Start
- 2022-12-14
- Primary completion
- 2025-10-22
- Completion
- 2025-11-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hypericin | Other / unclassified | 0.25 % | Topical |